A wide range of multinational observational studies in individuals with T2DM and cardiovascular risk has also demonstrated that the beneficial effects of SGLT2 inhibitors are associated with MI and stroke, with AS and its clinical consequences being the most closely linked (93, 94). This evidence concerns the gene SLC5A2 and Stroke.